Analyses / Public Summary / 119 · HR 3490 Public Summary

119-HR-3490 Journalist Public Summary

119 · HR 3490 Gerald E. Connolly Esophageal Cancer Awareness Act of 2025

settings Government Operations and Politics
Esophageal Cancer Awareness ActThis bill requires the Government Accountability Office to report to Congress on (1) the impact of esophageal cancer-related health care spending under the Federal...

H.R. 3490 orders the GAO to study esophageal-cancer costs and screening practices in the Federal Employees Health Benefits (FEHB) program within one year; it passed the House on June 3, 2025, passed the Senate on May 20, 2026, and now heads to the President for signature.

Published
21 May 2026
Updated
21 May 2026
Tags
health policy · esophageal cancer · FEHB
Unvetted
01 · Section

Headline Summary

A bipartisan bill directing the Government Accountability Office to report on esophageal-cancer costs and screening in the FEHB program—now cleared by both chambers and headed to the President.

02 · Section

What It Does

The Gerald E. Connolly Esophageal Cancer Awareness Act of 2025 requires the Government Accountability Office (GAO) to deliver, within one year of enactment, a report to Congress on two things: (1) how much the Federal Employees Health Benefits (FEHB) program spends on care related to esophageal cancer for federal employees and retirees, and (2) how often FEHB enrollees who are considered high‑risk are getting screened according to established medical guidelines.

Why it matters: Esophageal cancer is aggressive and often detected late. Congress wants better data on costs and whether people at higher risk in one of the nation’s largest employer health plans are being screened as recommended—information that could guide future policy or outreach efforts.

03 · Section

Who’s For It

  • Bipartisan lawmakers: The bill passed the House by voice vote (June 3, 2025) and the Senate by unanimous consent (May 20, 2026), signaling broad support.
  • Sponsors and committee leaders emphasized awareness, early detection, and better data to inform benefits management and prevention efforts.
  • Stakeholders likely to favor it include patient‑advocacy and cancer‑research groups, given its focus on early detection and outcomes.
04 · Section

Who’s Against It

  • No recorded opposition: There were no roll‑call votes against it; the Senate cleared it by unanimous consent and the House approved it by voice vote.
  • Potential concerns (not formally raised in votes) could include added workload for GAO, data‑sharing and privacy considerations within FEHB, or whether a one‑time study will translate into actionable changes.
05 · Section

What’s Next

Since the Senate passed H.R. 3490 without amendment on May 20, 2026, the bill now proceeds to enrollment and presentation to the President. If signed into law, GAO will have one year from enactment to deliver its report to Congress.

Discussion